WASHINGTON – The Food and Drug Administration and vaccine maker Johnson & Johnson are expected to announce as early as Friday that contamination issues at a COVID-19 vaccine facility in Baltimore have been resolved, clearing the way for millions more doses.
Vaccine production in the factory of the contract manufacturer Emergent BioSolutions Inc.
EBS, + 0.61%
stopped after unsanitary conditions resulted in contamination of J&J
JNJ, -0.15%
Vaccinations. The facility manufactured vaccine substances and finished vaccine doses for J&J and AstraZeneca
AZN, + 0.62%
PLC.
